We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

This study has been terminated.
(PI relocated)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00438321
First Posted: February 22, 2007
Last Update Posted: April 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
National Institutes of Health (NIH)
American Diabetes Association
Information provided by (Responsible Party):
Frances Hayes, Massachusetts General Hospital
  Purpose
The purpose of the study is to examine the effect of testosterone treatment on insulin in men with the metabolic syndrome with testosterone levels at or below the lower end of the normal range.

Condition Intervention Phase
Metabolic Syndrome Drug: Zoladex Drug: Testosterone gel Drug: Anastrozole Pill Other: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome

Resource links provided by NLM:


Further study details as provided by Frances Hayes, Massachusetts General Hospital:

Primary Outcome Measures:
  • Insulin sensitivity [ Time Frame: 3 months ]
    Assessed by euglycemic-hyperinsulinemic clamp


Secondary Outcome Measures:
  • Resting energy expenditure [ Time Frame: 3 months ]
    Indirect calorimetry

  • Lipid profile [ Time Frame: 3 months ]
    Fasting lipids

  • Body composition [ Time Frame: 3 months ]
    DXA scan

  • Intramyocellular fat [ Time Frame: 3 months ]
    MR spectroscoopy


Enrollment: 66
Study Start Date: September 2006
Study Completion Date: February 26, 2010
Primary Completion Date: February 26, 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo injection, gel and pill
Other: Placebo
Active Comparator: Testosterone only
Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally daily Anastrozole 10 mg (Arimidex) orally daily
Drug: Zoladex Drug: Testosterone gel
Other Name: AndroGel
Drug: Anastrozole Pill
Other Name: Arimidex
Active Comparator: Testosterone and Estrogen
Zoladex 3.6 mg IM injection Testosterone 7.5 g gel (AndroGel) transdermally Placebo pill orally daily
Drug: Zoladex Drug: Testosterone gel
Other Name: AndroGel

Detailed Description:

The metabolic syndrome is a medical condition defined by high cholesterol levels, high blood pressure, increased abdominal obesity (gain in fat around the region of the stomach), and insulin resistance. Insulin is the hormone that your body produces to decrease the levels of sugar in your blood. A person that is insulin resistant needs more insulin to decrease blood sugar levels than a normal person does. Insulin resistance can lead to type 2 diabetes, which is one of the most common illnesses in the United States.

There is evidence pointing to a relationship between insulin and testosterone in men (testosterone is the male sex hormone that is produced in the testes). As men get older their testosterone levels decrease while their weight and insulin resistance tends to increase. The purpose of this research study is to learn more about the details of the relationship between insulin and testosterone. A clearer understanding of this relationship can have an important impact on public health due to the high rate of health problems associated with diabetes, obesity, and heart disease.

We are looking for men between the ages of 50-75 with the metabolic syndrome to participate in this research study. Participation in this study involves taking medication and/or placebo (a placebo looks exactly like the study medication but contains no active drug), blood tests, muscle biopsies, and imaging scans. This study involves outpatient visits. Subjects are paid up to $500 for completing the study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Stable weight for previous three months (no weight change greater than or equal to +/-10 lbs)

Exclusion Criteria:

  • No new diagnosis of type 2 diabetes or on oral hypoglycemic agents
  • No history of testicular disorders
  • No history of bleeding disorders (i.e. Pulmonary Embolism, Deep Vein Thrombosis, stroke, hypercoagulable syndrome)
  • No history of prostate cancer
  • No previous diagnosis of osteoporosis
  • No history of sleep apnea (subjects will also be excluded if at their baseline assessment they admit to heavy snoring, restless sleep, and/or excessive daytime somnolence)
  • No symptoms of urinary outflow obstruction or medications for prostate disease
  • No illicit drug use or heavy alcohol use (>4 drinks/day)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00438321


Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Institutes of Health (NIH)
American Diabetes Association
Investigators
Principal Investigator: Frances J Hayes, MD Massachusetts General Hospital
  More Information

Additional Information:
Publications:
Responsible Party: Frances Hayes, Associate Professor, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT00438321     History of Changes
Other Study ID Numbers: 2003-P-001526
First Submitted: February 20, 2007
First Posted: February 22, 2007
Last Update Posted: April 18, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Frances Hayes, Massachusetts General Hospital:
Overweight
obesity
testosterone
diabetes
metabolic syndrome
aging

Additional relevant MeSH terms:
Syndrome
Metabolic Syndrome X
Insulin Resistance
Disease
Pathologic Processes
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Testosterone
Testosterone enanthate
Testosterone undecanoate
Testosterone 17 beta-cypionate
Methyltestosterone
Anastrozole
Goserelin
Insulin
Androgens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Anabolic Agents
Hypoglycemic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists